Rocket Pharmaceuticals - RCKT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $51.25
  • Forecasted Upside: 127.78%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.54 (2.46%)

This chart shows the closing price for RCKT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rocket Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCKT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCKT

Analyst Price Target is $51.25
▲ +127.78% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Rocket Pharmaceuticals in the last 3 months. The average price target is $51.25, with a high forecast of $65.00 and a low forecast of $39.00. The average price target represents a 127.78% upside from the last price of $22.50.

This chart shows the closing price for RCKT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 10 investment analysts is to moderate buy stock in Rocket Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/3/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$49.00 ➝ $40.00Low
6/28/2024Chardan CapitalReiterated RatingBuy ➝ Buy$62.00 ➝ $62.00Low
6/28/2024Needham & Company LLCLower TargetBuy ➝ Buy$53.00 ➝ $52.00Low
6/3/2024William BlairReiterated RatingOutperformLow
5/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$53.00Low
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$53.00Low
4/2/2024The Goldman Sachs GroupInitiated CoverageNeutral$39.00Low
3/1/2024UBS GroupLower TargetBuy ➝ Buy$56.00 ➝ $54.00Low
2/27/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$55.00 ➝ $50.00Low
2/27/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00Low
2/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$53.00Low
1/31/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00Low
12/26/2023Lifesci CapitalReiterated RatingOutperformLow
11/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$53.00Low
10/24/2023Cantor FitzgeraldInitiated CoverageOverweight$65.00Low
9/13/2023Stifel NicolausReiterated RatingBuy ➝ Buy$48.00Low
9/13/2023Needham & Company LLCLower TargetBuy ➝ Buy$60.00 ➝ $53.00Low
8/11/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$49.00 ➝ $47.00Low
8/11/2023Chardan CapitalReiterated RatingBuy ➝ Buy$61.00Low
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00Low
8/10/2023Stifel NicolausLower TargetBuy ➝ Buy$53.00 ➝ $48.00Low
5/5/2023Chardan CapitalLower Target$63.00 ➝ $61.00Low
4/19/2023Needham & Company LLCReiterated RatingBuy$60.00Low
3/22/2023William BlairReiterated RatingOutperformLow
3/1/2023Chardan CapitalLower TargetBuy$65.00 ➝ $63.00Low
2/28/2023Needham & Company LLCReiterated RatingBuy$60.00Low
2/1/2023Morgan StanleyInitiated CoverageOverweight$45.00Low
1/23/2023SVB LeerinkLower TargetOutperform$50.00 ➝ $49.00Low
12/23/2022Bank of AmericaLower TargetBuy$38.00 ➝ $35.00Low
12/22/2022SVB LeerinkLower TargetOutperform$54.00 ➝ $50.00Low
12/6/2022SVB LeerinkLower TargetOutperform$56.00 ➝ $54.00Low
11/8/2022Canaccord Genuity GroupInitiated CoverageBuy$53.00Low
11/7/2022Canaccord Genuity GroupInitiated CoverageBuy$53.00Low
11/4/2022Needham & Company LLCLower TargetBuy$62.00 ➝ $60.00Low
11/1/2022BTIG ResearchInitiated CoverageBuy$35.00Low
10/3/2022Raymond JamesBoost TargetOutperform$24.00 ➝ $34.00Low
9/30/2022SVB LeerinkLower TargetOutperform$65.00 ➝ $60.00Low
9/30/2022Chardan CapitalBoost TargetBuy$62.00 ➝ $65.00Low
9/30/2022Evercore ISIBoost TargetOutperform$65.00 ➝ $75.00Low
9/27/2022UBS GroupLower TargetBuy$68.00 ➝ $62.00Low
8/9/2022Raymond JamesBoost TargetOutperform$22.00 ➝ $24.00Low
7/8/2022Raymond JamesInitiated CoverageOutperformN/A
7/6/2022SVB LeerinkLower TargetOutperform$66.00 ➝ $64.00N/A
5/20/2022SVB LeerinkBoost TargetOutperform$64.00 ➝ $66.00High
5/19/2022Chardan CapitalBoost TargetBuy$60.00 ➝ $62.00High
5/19/2022Stifel NicolausBoost Target$63.00 ➝ $67.00High
5/17/2022Needham & Company LLCLower TargetBuy$75.00 ➝ $62.00High
5/5/2022William BlairReiterated RatingOutperformHigh
4/12/2022Needham & Company LLCReiterated RatingBuy$75.00Medium
2/24/2022SVB LeerinkBoost TargetOutperform$62.00 ➝ $64.00High
12/15/2021Chardan CapitalBoost TargetBuy$56.00 ➝ $60.00High
10/24/2021Lifesci CapitalReiterated RatingOutperformLow
10/24/2021SVB LeerinkReiterated RatingBuyLow
9/19/2021SVB LeerinkReiterated RatingBuyHigh
9/7/2021Chardan CapitalReiterated RatingBuyMedium
8/19/2021SVB LeerinkReiterated RatingBuyHigh
8/10/2021Chardan CapitalReiterated RatingBuy$56.00Medium
8/10/2021Needham & Company LLCReiterated RatingBuy$75.00Medium
8/10/2021SVB LeerinkLower TargetOutperform$66.00 ➝ $62.00Medium
8/10/2021William BlairReiterated RatingBuyMedium
7/7/2021Chardan CapitalReiterated RatingBuyLow
4/1/2021SVB LeerinkBoost TargetOutperform$61.00 ➝ $66.00Medium
3/1/2021Stifel NicolausInitiated CoverageBuy$64.00High
2/18/2021Needham & Company LLCInitiated CoverageBuy$75.00Medium
1/4/2021Piper SandlerBoost Target$60.00 ➝ $80.00N/A
12/15/2020UBS GroupInitiated CoverageBuy$75.00Medium
12/10/2020Evercore ISIBoost TargetOutperform$65.00 ➝ $100.00High
12/8/2020Chardan CapitalBoost TargetPositive ➝ Buy$35.00 ➝ $46.00High
12/8/2020Piper SandlerBoost TargetOverweight$35.00 ➝ $50.00High
12/8/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
11/23/2020JPMorgan Chase & Co.Boost TargetOverweight$38.00 ➝ $43.00High
11/4/2020SVB LeerinkReiterated RatingOutperformMedium
10/16/2020Lifesci CapitalReiterated RatingOutperformLow
10/16/2020Chardan CapitalBoost TargetBuy$33.00 ➝ $35.00High
9/22/2020OppenheimerLower TargetOutperform$43.00 ➝ $33.00Low
8/9/2020CowenReiterated RatingBuyMedium
8/5/2020Ci CapitalReiterated RatingBuy$35.00High
7/13/2020OppenheimerReiterated RatingBuy$43.00High
7/13/2020Chardan CapitalReiterated RatingBuy$33.00High
7/2/2020JPMorgan Chase & Co.Initiated CoverageOverweight$38.00High
6/25/2020Bank of AmericaInitiated CoverageBuy$34.00High
6/1/2020OppenheimerInitiated CoverageBuyMedium
5/6/2020William BlairReiterated RatingBuyMedium
3/11/2020Chardan CapitalReiterated RatingBuy$33.00High
3/5/2020William BlairReiterated RatingBuyHigh
3/5/2020Chardan CapitalReiterated RatingBuy$33.00Low
12/9/2019OppenheimerBoost TargetOutperform$36.00 ➝ $42.00Low
12/6/2019Chardan CapitalReiterated RatingBuy$30.00Low
12/6/2019Robert W. BairdBoost TargetOutperform$30.00 ➝ $41.00High
11/17/2019CowenReiterated RatingBuyLow
11/7/2019CowenReiterated RatingBuyHigh
11/5/2019Chardan CapitalInitiated CoverageBuy$30.00High
9/26/2019Piper Sandler CompaniesInitiated CoverageOverweightHigh
9/10/2019William BlairReiterated RatingBuyHigh
9/4/2019William BlairReiterated RatingBuyLow
8/22/2019William BlairReiterated RatingBuyLow
8/13/2019OppenheimerLower TargetOutperform$39.00 ➝ $37.00Medium
(Data available from 7/14/2019 forward)

News Sentiment Rating

0.81 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 4 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
  • 9 very positive mentions
  • 21 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
  • 16 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 12 very positive mentions
  • 25 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 9 very positive mentions
  • 25 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 11 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 10 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 10 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Rocket Pharmaceuticals logo
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Read More

Today's Range

Now: $22.50
Low: $21.62
High: $22.70

50 Day Range

MA: $22.00
Low: $19.78
High: $24.06

52 Week Range

Now: $22.50
Low: $14.89
High: $32.53


778,684 shs

Average Volume

1,020,733 shs

Market Capitalization

$2.04 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Rocket Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Rocket Pharmaceuticals in the last year: Canaccord Genuity Group Inc., Cantor Fitzgerald, Chardan Capital, JPMorgan Chase & Co., Lifesci Capital, Needham & Company LLC, Stifel Nicolaus,, The Goldman Sachs Group, Inc., UBS Group AG, and William Blair.
View the latest analyst ratings for RCKT.

What is the current price target for Rocket Pharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for Rocket Pharmaceuticals in the last year. Their average twelve-month price target is $51.25, suggesting a possible upside of 127.8%. Cantor Fitzgerald has the highest price target set, predicting RCKT will reach $65.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $39.00 for Rocket Pharmaceuticals in the next year.
View the latest price targets for RCKT.

What is the current consensus analyst rating for Rocket Pharmaceuticals?

Rocket Pharmaceuticals currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RCKT.

What other companies compete with Rocket Pharmaceuticals?

How do I contact Rocket Pharmaceuticals' investor relations team?

Rocket Pharmaceuticals' physical mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company's listed phone number is (609) 659-8001 and its investor relations email address is [email protected]. The official website for Rocket Pharmaceuticals is Learn More about contacing Rocket Pharmaceuticals investor relations.